Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer
NCT03485729Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Mar 2018
- Primary completion
- Jan 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in endometrial cancer (EC), sponsored by Chimerix Inc.. Started Mar 2018; status: terminated.
02
Drugs
dordaviprone
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03485729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485729.